Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies (NYSE: A) launched the NovoStation Sample Preparation System to automate sample preparation for laboratory flow cytometry workflows.
The platform automates reagent mixing and sample washing and connects with compatible Agilent flow cytometers. Paired with NovoCyte and NovoExpress software, it is designed to connect preparation with data acquisition. Agilent reported that validation studies reduced hands-on time by more than 90%, with data quality comparable to manual processing. The company will officially unveil NovoStation at the International Clinical Cytometry Society conference in Miami, taking place October 2–6, 2026.
Agilent Technologies (A) launched the BioTek Gen5 AI cell identification module for compatible BioTek automated imaging systems.
The software add-on brings AI-based cell identification and segmentation into Gen5 imaging analysis without conventional threshold setting or parameter tuning. It works within Gen5 on compatible Cytation and Lionheart automated imagers. Agilent says the module is designed to reduce manual image-analysis steps and support consistent cell counting and confluence analysis across supported applications.
Agilent Technologies (A) launched the 4150 TapeStationDx system, 4200 TapeStationDx system and TapeStationDx software to bring its automated electrophoresis platform into regulated clinical NGS sample quality control workflows.
The CE-IVD-labeled systems are designed to standardize and document DNA and RNA quality control for clinical next-generation sequencing, with automated workflows to reduce manual errors and support consistent operation. The 4150 TapeStationDx targets lower-throughput labs, handling 1 to 16 samples in tube strips, while the 4200 TapeStationDx scales from 1 to 96 samples using tube strips or 96-well plates at a constant cost per sample. Both systems provide quality control results in about 1 to 2 minutes per sample. TapeStationDx software manages data acquisition, analysis, reporting and export, and includes audit trails and electronic signatures to help support compliance with regulations such as 21 CFR Part 11 and EU Annex 11.
The portfolio is available in the United States, Canada and selected European countries. Agilent reports fiscal 2025 revenue of $6.95 billion and around 18,000 employees worldwide.
Agilent Technologies (A) declared a quarterly cash dividend of 25.5 cents per share of common stock. The dividend is scheduled to be paid on October 6, 2026, to shareholders of record as of the close of business on October 28, 2026. The company states that the timing and amount of future dividends will depend on determinations by Agilent’s board of directors. In fiscal year 2025, Agilent generated $6.95 billion in revenue and employed approximately 18,000 people worldwide.
Agilent Technologies (A) declared a quarterly cash dividend of 25.5 cents per share of common stock. The dividend is scheduled to be paid on October 28, 2026 to shareholders of record as of the close of business on October 6, 2026. Future dividend timing and amounts will depend on determinations by Agilent’s board of directors. The company reports revenue of $6.95 billion for fiscal year 2025 and approximately 18,000 employees worldwide.
Agilent Technologies (A) will participate in a fireside chat at the J.P. Morgan U.S. All Stars Conference at 10 a.m. BST on Sept. 23, 2026, in London.
CEO Padraig McDonnell and CFO Adam Elinoff are scheduled to speak. A live audio webcast and replay of the presentation will be available via Agilent’s Investor Relations website. The company reports revenue of $6.95 billion for fiscal year 2025 and has approximately 18,000 employees worldwide.
Agilent Technologies (A) announced the retirement of independent board chair Koh Boon Hwee, effective Sept. 4, 2026, after more than 20 years as a director.
He joined the board in 2003, became independent chair in 2017, and led the Executive Committee and the Nominating and Corporate Governance Committee. Following his retirement, the board elected Dow R. Wilson as chair, also effective Sept. 4, 2026; Wilson has served as a director since 2018 and chairs the Audit and Finance Committee. Agilent also appointed Glenn Boehnlein, former Stryker Corporation CFO, to its board on the same date. The company reports fiscal 2025 revenue of $6.95 billion and a workforce of about 18,000 employees worldwide.
Agilent Technologies (A) has launched the Agilent S540MD Slide Scanner System in the United States, a whole slide imaging digital scanner cleared by the FDA for use in digital pathology workflows.
The S540MD supports up to 540 slides, offers continuous loading and standard rack compatibility, and includes automated scanning modes with advanced tissue detection to help high-volume pathology laboratories digitize glass slides efficiently. The scanner is an Agilent-branded version of the Hamamatsu NanoZoomer S540MD system. Agilent states that this launch strengthens its digital pathology portfolio and supports laboratories facing rising sample volumes and the shift toward digital and AI-enabled workflows. The system is now available across the U.S. and in multiple European markets following an earlier launch in select European countries in January 2026.
Agilent Technologies (NYSE: A) has launched the Cary 635 FTIR spectrometer, a compact, high-performance Fourier transform infrared system designed to meet modern laboratory demands for efficiency, reliability, and space savings. The instrument features solid ZnSe optics for moisture resistance, improved sensitivity for lower-concentration samples, and a highly modular architecture that supports solids, liquids, powders, and gases.
The Cary 635 FTIR incorporates a nondynamic interferometer, permanently aligned optics for rapid module changes, and compatibility with the Agilent DialPath module to simplify liquid measurements while reducing consumables and sample volume. Method-driven MicroLab software offers guided workflows and color-coded results, enabling rapid training of users and supporting both routine and complex applications. Agilent reports fiscal 2025 revenue of $6.95 billion and a workforce of about 18,000 employees worldwide.
Agilent (NYSE: A) reported third-quarter fiscal 2026 revenue of $1.88 billion, up 8.1% reported and 7.3% core versus Q3 2025. GAAP operating margin reached 23.6%, while non-GAAP operating margin was 28.3%, including an approximately 110 bps net benefit from tariff refunds. GAAP net income was $362 million (EPS $1.28), and non-GAAP net income was $459 million with EPS of $1.62, up 18% year-over-year.
By segment, Life Sciences and Diagnostics revenue was $746 million (+11% reported), Agilent CrossLab $786 million (+6%), and Applied Markets $346 million (+7%). Agilent raised its fiscal 2026 outlook, guiding revenue to $7.49–$7.51 billion (7.8%–8.1% reported growth) and non-GAAP EPS to $6.18–$6.21. Fourth-quarter 2026 revenue is expected at $1.98–$2.0 billion with non-GAAP EPS of $1.71–$1.74, excluding any future tariff refund benefits.